ONCO — Oncopeptides AB Income Statement
0.000.00%
- SEK618.31m
- SEK652.91m
- SEK35.22m
Annual income statement for Oncopeptides AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 118 | 8.36 | 35.2 |
Cost of Revenue | |||||
Gross Profit | — | — | 65.2 | 8.35 | 36.3 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 739 | 1,591 | 1,539 | 358 | 289 |
Operating Profit | -739 | -1,591 | -1,421 | -349 | -253 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -740 | -1,592 | -1,421 | -338 | -248 |
Provision for Income Taxes | |||||
Net Income After Taxes | -741 | -1,595 | -1,430 | -338 | -249 |
Net Income Before Extraordinary Items | |||||
Net Income | -741 | -1,595 | -1,430 | -338 | -249 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -741 | -1,595 | -1,430 | -338 | -249 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -10.2 | -18.2 | -13.5 | -2.93 | -1.96 |
Dividends per Share |